Category: Technology Licenses
Created On: 2022-04-28
Record Count: 8
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 789
Extended Release Buccal Bioadhesive Tablet The present invention relates to a bioadhesive, bioerodible tablet for the extended and controlled release of active ingredients. More particularly, the present invention relates to a progressive hydration tablet for adhesion to the wall of a body cavity for the sustained release of active ingredients without premature degradation of the active ingredients caused by metabolism, or by moisture, enzymes or pH effects.
Patents and Applications
Patent No. Title Country Current Status Expiration Date
1,105,104 Extended Release Buccal Bioadhesive Tablet
United Kingdom Issued 8/24/2019
France Issued 8/24/2019
Switzerland Issued 8/24/2019
Austria Issued 8/24/2019
Spain Issued 8/24/2019
Sweden Issued 8/24/2019
Denmark Issued 8/24/2019
Netherlands Issued 8/24/2019
Belgium Issued 8/24/2019
Italy Issued 8/24/2019
Ireland Issued 8/24/2019
Portugal Issued 8/24/2019
Monaco Issued 8/24/2019
Finland Issued 8/24/2019
Cyprus Issued 8/24/2019
Luxembourg Issued 8/24/2019
3,055,843 Extended Release Buccal Bioadhesive Tablet
Greece Issued 8/24/2019
226,591 Extended Release Buccal Bioadhesive Tablet
Hungary Issued 8/24/2019
2/8/69927694 Extended Release Buccal Bioadhesive Tablet
Germany Issued 8/24/2019
Extended Release Buccal Bioadhesive Tablet
Norway Pending 8/24/2019
IPSCIO Record ID: 7516
Invention shall thereafter mean the inventions covered by any claim(s) of a Patent issued or validated in the USA, the United Kingdom, France or Germany and not subsequently invalidated.
Israel Patent Application 123998 (which is priority document for all patents/patent applications listed below)
PCT/IL99/00173 (all patents/patent applications listed below via this application).
Europe European Patent Application EP 1071702 B1 covering Austria Belgium Cyprus Denmark Finland France Germany Greece
Other European Applications
P 01 01653
P 343 360
Eurasian Application No. 200000888 covering
United States 6,395,722(granted), 6,384,024(granted), 10/078,671
IPSCIO Record ID: 26186
The Patents relate to Oracea, the Companyâ€™s dermatology product for the systemic treatment of rosacea. Methods of treating acne.
IPSCIO Record ID: 209489
Intellectual Property and Intellectual Property Rights means the trade marks and Patent Rights. The patent information is referred to as Solarase I, II, and III.
Solaraze Gel is a treatment for the chronic skin condition actinic keratosis.
Actinic keratosis is a pre-cancerous patch of thick, scaly, or crusty skin.
IPSCIO Record ID: 4374
VIBATIVÂ® is for the treatment of nosocomial pneumonia (hospital-acquired), including ventilator-associated pneumonia, known or suspected to be caused by MRSA when other alternatives are not suitable.
VIBATIVÂ® is a bactericidal, once-daily injectable lipoglycopeptide antibiotic approved in the U.S. and Canada for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria, including Staphylococcus aureus, both methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) strains.
IPSCIO Record ID: 203465
XyremÂ® is (sodium oxybate) oral solution. Trademarkâ€ means the trademark XyremÂ®
Xyrem is used to treat narcolepsy.
IPSCIO Record ID: 28567
Sublicenses. Licensee shall have the right to grant sublicenses (with rights to further sublicense) under the licenses to sublicensees, provided that Licensee shall ensure that its sublicensees shall be subject to a written agreement with terms and conditions that are consistent with, and no less protective of, Licensor than the terms and conditions hereunder.
Licensed Intellectual Property means (a) the Licensed Trade Dress; (b) the Licensed Patents; (c) the Licensed Know How; and (d) the Licensed Inventions.
Licensed Inventions means (a) the Licensor Inventions; and (b) Licensor's and its Affiliates' interest in and to the Joint Inventions.
Licensed Trade Dress means the layout, designs and coloring used on the packaging of the Product solely to the extent also used by the Licensor or its current Affiliates on product packaging of their products other than the Products.
Licensed Know How means all the know-how, trade secrets, expertise, inventions, discoveries, technical information and other unpatented information related to the Product that is owned or controlled by, or licensed to, Licensor or its Affiliates, including, but not limited to, all information reasonably necessary for Licensee and its Affiliates to make, have made, use or sell the Product, but expressly excluding any Product Know How as defined in the APA, which Product Know How is assigned to Licensee pursuant to the APA executed concurrently herewith.
STRIANTÂ® (testosterone buccal system) was approved by the FDA in June 2003 for a deficiency or absence of endogenous testosterone associated with hypogonadism in men.
This novel product uses our buccal delivery technology to deliver testosterone across the buccal mucosa (the lining of the cheek and gum) and into the bloodstream in a controlled, sustained manner.
Licensed Patents – 6,248,358 – Bioadhesive Progressive Hydration Tablets and Methods of making and using the same. A bio adhesive tablet wherein the active ingredient may be protected from water or the surrounding environment, thereby protecting it from metabolism or from other degradation caused by moisture, enzymes, or pH effects, and making it bioavailable only at a controlled rate. The active ingredient may be protected from moisture during the manufacturing process and more importantly may be protected from moisture and the immediate septic environment until after the patient has applied the tablet, and then only at a slow and controlled rate. It is by this process of progressive hydration that the active ingredient remains protected for many hours after administration. It is also by the process of progressive hydration that controlled and sustained release is achieved because only that part of the active ingredient that is the hydrated (aqueous) fraction of the tablet is available for absorption (bioavailable).
IPSCIO Record ID: 279330
API means Active Pharmaceutical Ingredient.